Decoding lung health thru Aerosol Biopsy
Deton wins Swimming with the Sharks Competition
by Deton Corp. on March 22nd, 2017

​Most Promising Company at the 2017 Molecular Medicine Tri-Conference
​On February 22, 2017, Deton CEO and Co-Founder Patrick Sislian, PhD took 1st place at the 2017 Molecular Medicine Tri-Conference “Swimming with the Sharks” competition in San Francisco.  Deton was chosen as the Most Promising Company by a panel of judges consisting of venture capitalists, angels, and diagnostic industry executives. The judges noted that Deton had a well thought out go-to-market strategy, a unique solution addressed a large unmet clinical need, and a clear ask.  “We at Deton are incredibly excited and grateful for this diagnostic industry award,” said Sislian. “The future of medicine is increasingly evidence-based and our win shows the the Cough Collector is well positioned to enable lower respiratory disease diagnosis.”

Deton presented as one of the 8 finalists selected from numerous applicants to this year’s competition from across molecular medicine, including drug discovery, genomics, diagnostics and information technology.  The other finalists were: Abreos Biosciences, Envision Genomics, Nephrogen Sciences, Selfdiagnostics, Geneoscopy, PrecisionProfile, SpinDiag. 
About Molecular Medicine Tri-Conference
Attracting over 3,500 drug discovery and development professionals from over 40 countries in 2016, the Molecular Medicine Tri-Conference has grown into a diverse event, focusing on Molecular Medicine, specifically on Discovery, Genomics, Diagnostics and Information Technology.  This conference features over 500 speakers from across all industries and research fields across the world as well as over 400 presentations and panel discussions, 30 roundtable discussions and over 200 companies exhibiting.  Back by popular demand is the "Swimming with the Sharks" competition.  Companies seeking venture funding will pitch their company's value proposition to a panel of judges and the top place winner will receive recognition as the "2017 Tri-Con Most Promising Company".

About Deton
Deton is promoting lung health by enabling diagnosis of disease through the collection, management, and analysis of cough aerosols. Deton’s solution, the Cough Collector, will make diagnosing lower respiratory infections easy, rapid and reliable, paving the way for targeted treatments and better patient outcomes. Armed with the evidence, doctors will be able to prescribe antibiotics empowered with reliable information. Deton is headquartered in Pasadena, California (Los Angeles). For more information, please visit 

Posted in not categorized    Tagged with no tags